Carnegie Investment Bank
Diamyd Medical
Date Title Alternative
2024-04-24 An exciting future on the cards Download | Show Close
2024-01-26 All eyes on DIAGNODE-3 Download | Show Close
2023-11-09 Cash chest refilled Show Close
Research | 9 Nov 2023 | Diamyd Medical

Cash chest refilled

 

Rights issue completed

Diamyd has announced the final results of its rights issue. In total, some 32% of the offered units were subscribed to, providing the company with around SEK 78m before costs. Moreover, warrants now also available in the market could provide additional capital in the future. Given its current cash position and the rights issue, we consider Diamyd to be financed until the start of 2025.

Expecting a fully recruited study during 2024

DIAGNODE-3 is running according to schedule, and clinicaltrials.gov says 12 clinics are now active in the US, three of which have started recruiting patients. We believe the timetable is unchanged, meaning the study should be fully recruited during 2024.

New fair value following rights issue

In the wake of the rights issue and given certain estimate adjustments on the cost side, we have a new fair value of SEK 15–16 (18–20) per share.

 

Download (EN)
2023-10-12 Rights issue to be implemented Show Close
2023-06-30 Money in the bank Show Close
2023-04-20 Diabetes deal Show Close
2023-04-11 In a solid position Show Close

Vi använder cookies för att anpassa innehåll och annonser, för att tillhandahålla funktioner för sociala medier och för att analysera vår trafik. Vi delar också information om din användning av vår webbplats med våra partners inom sociala medier, annonsering och analys, som kan kombinera den med annan information som du har lämnat till dem eller som de har samlat in från din användning av deras tjänster. Du samtycker till våra cookies om du fortsätter att använda vår webbplats.

Inställningar Tillåt alla Inaktivera alla